Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.36 HKD
Change Today +0.10 / 0.75%
Volume 232.0K
As of 10:06 PM 04/20/15 All times are local (Market data is delayed by at least 15 minutes).

china shineway pharmaceutica (2877) Snapshot

Open
$13.34
Previous Close
$13.26
Day High
$13.52
Day Low
$13.22
52 Week High
04/9/15 - $16.00
52 Week Low
03/25/15 - $10.96
Market Cap
11.0B
Average Volume 10 Days
3.6M
EPS TTM
$0.85
Shares Outstanding
827.0M
EX-Date
06/4/15
P/E TM
12.6x
Dividend
$0.23
Dividend Yield
3.08%
Current Stock Chart for CHINA SHINEWAY PHARMACEUTICA (2877)

Related News

No related news articles were found.

china shineway pharmaceutica (2877) Related Businessweek News

No Related Businessweek News Found

china shineway pharmaceutica (2877) Details

China Shineway Pharmaceutical Group Limited, an investment holding company, is engaged in the research, development, manufacture, and trading of prescription and OTC Chinese medicine injections, soft capsules, and granules in the People’s Republic of China and Hong Kong. Its principal products comprise Qing Kai Ling injection used as an anti-viral medicine for the treatment of viral diseases, including respiratory tract infection, viral hepatitis, cerebral haemorrhage, and cerebral thrombosis; Shen Mai injection for the treatment of coronary heart diseases, viral myocarditis, and pulmonary heart diseases; Shu Xie Ning injection for the treatment of cardio-cerebrovascular diseases; and Wu Fu Xin Nao Qing soft capsule for the prevention and treatment of coronary heart diseases and cerebral arteriosclerosis. The company’s products also include Huo Xiang Zheng Qi soft capsule for the prevention and treatment of heat stroke, stomachache, nausea and diarrhoea, and acclimatization sickness; and Pediatric Qing Fei Hua Tan granule for children infected by respiratory related diseases. In addition, it offers Huang Qi injection for the treatment of viral myocarditis, heart malfunction, and hepatitis; Qing Kai Ling soft capsules for the treatment of high fever, viral influenza, and respiratory tract infections; Huamoyan granule for the treatment of acute and chronic synovitis, as well as for after joints surgery treatment; Shujin Tongluo granule for the treatment of spondylosis and neck stiffness, as well as for symptoms comprising neck, shoulder, and back pains; and Jiangzhi Tongluo soft capsules for the treatment of symptoms, such as hyperlipidemia, chest and hypochondrium pain, and chest tightness. The company is headquartered in Shijiazhuang, the People’s Republic of China. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited.

china shineway pharmaceutica (2877) Top Compensated Officers

Co-Founder, Executive Chairman, President and...
Total Annual Compensation: CNY30.3M
Co-Founder, Executive Director and Member of ...
Total Annual Compensation: CNY740.0K
Executive Director
Total Annual Compensation: CNY749.0K
Executive Director
Total Annual Compensation: CNY675.0K
Executive Assistant and Executive Director
Total Annual Compensation: CNY435.0K
Compensation as of Fiscal Year 2013.

china shineway pharmaceutica (2877) Key Developments

China Shineway Pharmaceutical Group Limited Proposes Final and Special Dividend for the Year Ended December 31, 2014, Payable on June 19, 2015; Reports Audited Consolidated Earnings Results for the Year Ended December 31, 2014

In respect of the year ended 31 December 2014, the Directors of China Shineway Pharmaceutical Group Limited proposed that a final dividend of RMB 12 cents (2013: RMB 12 cents) per share and a special dividend of RMB 10 cents (2013: RMB 10 cents) per share will be paid on June 19, 2015, to shareholders of the company whose names appear on the register of members of the company on June 9, 2015. These dividends are subject to approval by the shareholders at the forthcoming AGM. The company reported audited consolidated earnings results for the year ended December 31, 2014. For the period, the company reported turnover of RMB 2,229,201,000 against RMB 2,187,115,000 a year ago. Profit before taxation was RMB 863,736,000 against RMB 859,646,000 a year ago. Profit and total comprehensive income attributable to owners of the company was RMB 704,775,000 or 85 cents basic and diluted earnings per share against RMB 683,647,000 or 83 cents basic earnings per share a year ago. Profit for the year increased mainly attributable to the increase in turnover and operating profit.

China Shineway Pharmaceutical Group Limited to Report Fiscal Year 2014 Final Results on Mar 27, 2015

China Shineway Pharmaceutical Group Limited announced that they will report fiscal year 2014 final results on Mar 27, 2015

China Shineway Pharmaceutical Group Limited, Board Meeting, Mar 27, 2015

China Shineway Pharmaceutical Group Limited, Board Meeting, Mar 27, 2015. Agenda: To approve the publication of final results of the company and its subsidiaries for the year ended 31 December 2014; and to consider the declaration of final dividend.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2877:HK $13.36 HKD +0.10

2877 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2877.
View Industry Companies
 

Industry Analysis

2877

Industry Average

Valuation 2877 Industry Range
Price/Earnings 12.5x
Price/Sales 3.9x
Price/Book 1.8x
Price/Cash Flow 12.5x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHINA SHINEWAY PHARMACEUTICA, please visit www.shineway.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.